Meeting Banner
Abstract #1907

A NIR830-Bevacizumab-Conjugated Iron Oxide Nanoparticle Probe for Vascular Endothelial Growth Factor (VGEF) Targeted MRI

Run Lin 1,2 , Jing Huang 1 , Liya Wang 1 , Yuancheng Li 1 , Prieto Ventura Veronica E 1 , Kevin Kim 1 , and Hui Mao 1

1 Department of Radiology and Imaging Sciences, Emory University School of Medicine, Atlanta, GA, United States, 2 Department of Radiology, the First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong, China

Vascular endothelial growth factor (VEGF) plays a pivotal role in the cascade of development and progression of cancers by promoting angiogenesis. Targeting this biomarker would be a logical strategy for imaging based cancer detection and anti-angiogenesis treatment. Bevacizumab is a recombinant humanized monoclonal antibody directly against VEGF and is currently used in clinic for treating various cancers with VEGF overexpression. In this study, a VEGF targeted molecular imaging probe was developed by conjugating near infrared dye (NIR830) labeled bevacizumab to magnetic iron oxide nanoparticles (IONP) for optical and magnetic resonance (MR) imaging of cancers overexpressing VEGF.

This abstract and the presentation materials are available to members only; a login is required.

Join Here